{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:33:57Z","timestamp":1766486037788,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jphs.2021.12.001","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T20:10:50Z","timestamp":1638907850000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Post-stroke treatment with K-134, a phosphodiesterase 3 inhibitor, improves stroke outcomes in the stroke-prone spontaneously hypertensive rat model\u2013A comparative evaluation of antiplatelet drugs"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4224-4487","authenticated-orcid":false,"given":"Hideo","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhana","family":"Ferdousi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2021.12.001_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0038-1649503","article-title":"Global burden of stroke","volume":"38","author":"Katan","year":"2018","journal-title":"Semin Neurol"},{"year":"2000","series-title":"Caplan's stroke: a clinical approach","author":"Caplan","key":"10.1016\/j.jphs.2021.12.001_bib2"},{"key":"10.1016\/j.jphs.2021.12.001_bib3","first-page":"436","article-title":"Recurrent ischemic stroke: strategies for prevention","volume":"96","author":"Oza","year":"2017","journal-title":"Am Fam Physician"},{"issue":"52","key":"10.1016\/j.jphs.2021.12.001_bib4","first-page":"e364","article-title":"Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart association\/American stroke association","volume":"2021","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2021.12.001_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"36","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jphs.2021.12.001_bib6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"SPS3 Investigators","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jphs.2021.12.001_bib7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.12.002","article-title":"Efficacy and safety of cilostazol therapy in ischemic stroke: a meta-analysis","volume":"24","author":"Tan","year":"2015","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jphs.2021.12.001_bib8","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1161\/STROKEAHA.119.026655","article-title":"Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and meta-analysis","volume":"50","author":"Kim","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2021.12.001_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jphs.2021.12.001_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00002512-199914010-00005","article-title":"Cilostazol","volume":"14","author":"Sorkin","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jphs.2021.12.001_bib11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jphs.2021.12.001_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1160\/TH10-07-0439","article-title":"Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation","volume":"105","author":"Yoshida","year":"2011","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.jphs.2021.12.001_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.atherosclerosis.2011.12.044","article-title":"A\u00a0phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease","volume":"221","author":"Yoshida","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jphs.2021.12.001_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046432","article-title":"K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model","volume":"7","author":"Yoshida","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2021.12.001_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(13)70060-7","article-title":"Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging","volume":"12","author":"Wardlaw","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jphs.2021.12.001_bib16","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1161\/STROKEAHA.108.528430","article-title":"Potential animal models of lacunar stroke: a systematic review","volume":"40","author":"Bailey","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2021.12.001_bib17","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/jcbfm.2008.91","article-title":"Do in\u00a0vivo experimental models reflect human cerebral small vessel disease? A systematic review","volume":"28","author":"Hainsworth","year":"2008","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.jphs.2021.12.001_bib18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1747-4949.2011.00659.x","article-title":"Is the spontaneously hypertensive stroke prone rat a pertinent model of sub cortical ischemic stroke? A systematic review","volume":"6","author":"Bailey","year":"2011","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jphs.2021.12.001_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam9507","article-title":"Reversal of endothelial dysfunction reduces white matter vulnerability in cerebral small vessel disease in rats","volume":"10","author":"Rajani","year":"2018","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"10.1016\/j.jphs.2021.12.001_bib20","first-page":"143","article-title":"Establishment of the stroke-prone spontaneously hypertensive rat (SHR)","volume":"34\/35","author":"Okamoto","year":"1974","journal-title":"Circ Res"},{"key":"10.1016\/j.jphs.2021.12.001_bib21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1253\/jcj.38.1095","article-title":"Importance of genetic factors in stroke: an evidence obtained by selective breeding of stroke-prone and -resistant SHR","volume":"38","author":"Yamori","year":"1974","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.jphs.2021.12.001_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1253\/jcj.46.274","article-title":"Symptomatological classification in the development of stroke in stroke-prone spontaneously hypertensive rats","volume":"46","author":"Yamori","year":"1982","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.jphs.2021.12.001_bib23","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/01.STR.20.9.1212","article-title":"Hemorrhagic stroke development in spontaneously hypertensive rats fed a North American, Japanese-style diet","volume":"20","author":"Smeda","year":"1989","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2021.12.001_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0167-4943(89)90003-4","article-title":"Effects of idebenone on neurological deficits following cerebrovascular lesions in stroke-prone spontaneously hypertensive rats","volume":"8","author":"Nagaoka","year":"1989","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.jphs.2021.12.001_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/01.STR.18.4.733","article-title":"Ultrastructural characteristics of occluded perforating arteries in stroke-prone spontaneously hypertensive rats","volume":"18","author":"Tagami","year":"1987","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2021.12.001_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF00690532","article-title":"Cerebral microangiopathy in stroke-prone spontaneously hypertensive rats. An immunohistochemical and ultrastructural study","volume":"75","author":"Fredriksson","year":"1988","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jphs.2021.12.001_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jns.2012.06.013","article-title":"Stases are associated with blood\u2013brain barrier damage and a restricted activation of coagulation in SHRSP","volume":"322","author":"Braun","year":"2012","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.jphs.2021.12.001_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0092-8674(00)80983-6","article-title":"Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor","volume":"84","author":"Savage","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.jphs.2021.12.001_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0092-8674(00)81607-4","article-title":"Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow","volume":"94","author":"Savage","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jphs.2021.12.001_bib30","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1073\/pnas.0608422104","article-title":"Shear-induced unfolding triggers adhesion of von Willebrand factor fibers","volume":"104","author":"Schneider","year":"2007","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.jphs.2021.12.001_bib31","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/jth.12422","article-title":"Mechanisms of hemolysis-associated platelet activation","volume":"11","author":"Helms","year":"2013","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.jphs.2021.12.001_bib32","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood-2008-09-180695","article-title":"Deficiency of von Willebrand factor protects mice from ischemic stroke","volume":"113","author":"Kleinschnitz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2021.12.001_bib33","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1182\/blood-2009-03-213264","article-title":"von Willebrand factor\u2013cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke","volume":"114","author":"Zhao","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2021.12.001_bib34","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/jth.12194","article-title":"Reduced prevalence of arterial thrombosis in von Willebrand disease","volume":"11","author":"Sanders","year":"2013","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.jphs.2021.12.001_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0006-2952(99)00346-9","article-title":"Potent effects of novel antiplatelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity","volume":"59","author":"Sudo","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jphs.2021.12.001_bib36","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.bcp.2003.12.028","article-title":"Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3","volume":"67","author":"Feijge","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jphs.2021.12.001_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000360811","article-title":"Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2","volume":"37","author":"Uchiyama","year":"2014","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jphs.2021.12.001_bib38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study","volume":"7","author":"Huang","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jphs.2021.12.001_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/jscd.2000.7216","article-title":"Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction","volume":"9","author":"Gotoh","year":"2000","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jphs.2021.12.001_bib40","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3390\/cells10081951","article-title":"cAMP compartmentalization in cerebrovascular endothelial cells: new therapeutic opportunities in alzheimer's disease","volume":"10","author":"Vina","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jphs.2021.12.001_bib41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.brainres.2016.06.036","article-title":"Cilostazol reduces blood brain barrier dysfunction, white matter lesion formation and motor deficits following chronic cerebral hypoperfusion","volume":"1646","author":"Edrissi","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.jphs.2021.12.001_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcn.2014.01.006","article-title":"Cilostazol attenuates ischemia-reperfusion-induced blood-brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-\u03b21 signaling","volume":"60","author":"Takeshita","year":"2014","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.jphs.2021.12.001_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0271678X15621499","article-title":"Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier","volume":"37","author":"Takagi","year":"2017","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.jphs.2021.12.001_bib44","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1161\/STROKEAHA.113.001183","article-title":"Cilostazol ameliorates warfarin-induced hemorrhagic transformation after cerebral ischemia in mice","volume":"44","author":"Kitashoji","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2021.12.001_bib45","doi-asserted-by":"crossref","first-page":"e15178","DOI":"10.1371\/journal.pone.0015178","article-title":"Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA","volume":"5","author":"Ishiguro","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2021.12.001_bib46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/STROKEAHA.111.635417","article-title":"Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model","volume":"43","author":"Kasahara","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.jphs.2021.12.001_bib47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jphs.2016.04.023","article-title":"Protective effects of cilostazol against hemorrhagic stroke: current and future perspectives","volume":"131","author":"Takagi","year":"2016","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2021.12.001_bib48","first-page":"219","article-title":"K-134, a phosphodiesterase 3 inhibitor, reduces vascular inflammation and hypoxia, and prevents rupture of experimental abdominal aortic aneurysms","volume":"1","author":"Unno","year":"2020","journal-title":"JVS: Vascular Science"},{"key":"10.1016\/j.jphs.2021.12.001_bib49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/jnr.23327","article-title":"Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation","volume":"92","author":"Omote","year":"2014","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.jphs.2021.12.001_bib50","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.brainres.2008.01.103","article-title":"Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats","volume":"1203","author":"Fujita","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.jphs.2021.12.001_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2040-7378-5-5","article-title":"NAC changes the course of cerebral small vessel disease in SHRSP and reveals new insights for the meaning of stases - a randomized controlled study","volume":"5","author":"Bueche","year":"2013","journal-title":"Exp Transl Stroke Med"},{"key":"10.1016\/j.jphs.2021.12.001_bib52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jphs.2021.10.007","article-title":"Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice","volume":"148","author":"Matsubara","year":"2022","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2021.12.001_bib53","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/01.HYP.0000164628.46415.66","article-title":"Chloride-dominant salt sensitivity in the stroke-prone spontaneously hypertensive rat","volume":"45","author":"Schmidlin","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jphs.2021.12.001_bib54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.HYP.6.1.49","article-title":"Possible role of nutritional factors in the incidence of cerebral lesions in stroke-prone spontaneously hypertensive rats","volume":"6","author":"Yamori","year":"1984","journal-title":"Hypertension"},{"key":"10.1016\/j.jphs.2021.12.001_bib55","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/B978-0-12-809657-4.66091-X","article-title":"Nutrition: soy and fish","author":"Yamori","year":"2018","journal-title":"Encycloped Cardiovas Res Med"},{"key":"10.1016\/j.jphs.2021.12.001_bib56","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1536\/ihj.17.404","article-title":"Prophylactic trials for stroke in stroke-prone SHR","volume":"17","author":"Yamori","year":"1976","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.jphs.2021.12.001_bib57","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1253\/jcj.44.347","article-title":"Stroke-prone SHR (SHRSP) as models for clinical and epidemiological studies on hypertension-related cardiac diseases in humans","volume":"44","author":"Ohtaka","year":"1980","journal-title":"Jpn Circ J"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132100116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132100116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:01:36Z","timestamp":1761163296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134786132100116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S134786132100116X"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2021.12.001","relation":{},"ISSN":["1347-8613"],"issn-type":[{"type":"print","value":"1347-8613"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-stroke treatment with K-134, a phosphodiesterase 3 inhibitor, improves stroke outcomes in the stroke-prone spontaneously hypertensive rat model\u2013A comparative evaluation of antiplatelet drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2021.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}